BELANTAMAB MAFODOTIN FOR INJECTION, 100 MG

Company name

GlaxoSmithKline UK

E-mail address of the competent person responsible for the Safety Data Sheet

msds@gsk.com

Signal word

Warning

Physical hazards

Not classified.

Health hazards

Germ cell mutagenicity Category 2 Reproductive toxicity Category 2 Specific target organ toxicity - repeated Category 2 exposure

Environmental hazards

Not classified.

Signal word

Warning

Hazard statements

Suspected of causing genetic defects. Suspected of damaging fertility or the unborn child. May cause damage to organs through prolonged or repeated exposure.

Prevention

Obtain special instructions before use. Do not handle until all safety precautions have been read and understood. Do not breathe dust. Use personal protective equipment as required.

Response

IF exposed or concerned: Get medical advice/attention.

Storage

Store locked up.

Disposal

Dispose of contents/container (in accordance with related regulations).

Other hazards which do not result in classification

Assume that this material is capable of sustaining combustion. Assume that this material is capable of being ignited by an electrostatic discharge. Assume that this material is capable of producing a dust explosion if ignited as a dust cloud. Caution - Potent pharmaceutical agent. See section 11 of the SDS for additional information on health hazards.

Additional information

99 % of the mixture consists of component(s) of unknown acute oral toxicity. 99 % of the mixture consists of component(s) of unknown acute dermal toxicity. 57 % of the mixture consists of component(s) of unknown acute inhalation toxicity. 99 % of the mixture consists of component(s) of unknown acute hazards to the aquatic environment. 99 % of the mixture consists of component(s) of unknown long-term hazards to the aquatic environment. Section 3: Composition and information of the ingredients of the hazardous chemical